Harvoni in combination with ribavirin for 12 weeks is now approved for use in chronic hepatitis C virus (HCV) genotype 1- or 4-infected liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh A), and for HCV genotype 1-infected patients with decompensated cirrhosis (Child-Pugh B/C), including those who have undergone liver transplantation.
The FDA approval was based on data from the Phase 2, open-label SOLAR-1 and SOLAR-2 trials. They evaluated 12 and 24 weeks of treatment with Harvoni in combination with ribavirin in HCV treatment-naive and treatment-experienced patients with genotype 1 and 4 infection who had undergone liver transplantation and/or who had decompensated liver disease. Pooled data showed that sustained virologic response at Week 12 (SVR12) among genotype 4 HCV post-transplant patients without cirrhosis, or with compensated cirrhosis, were similar to the reported genotype 1 SVR12 rates.
The expanded indications allow Harvoni to be used in more patient populations, including HCV genotypes 1, 4, 5, and 6, HCV/HIV-1 co-infection, HCV genotype 1 and 4 liver transplant recipients, and genotype 1-infected patients with decompensated cirrhosis.
Harvoni combines ledipasvir, an HCV NS5A inhibitor, and sofosbuvir, an HCV NS5B polymerase inhibitor. It is available as 90mg/400mg strength tablets in 28-count bottles.
For more information call (800) GILEAD-5 or visit Harvoni.com.